

# Testing the effects of low levels of blood oxygen and movement of the accuracy of portable vital signs monitors

<b>Submission date</b> 28/05/2019	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 10/06/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 19/07/2023	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Despite best efforts, there is continuing evidence that a proportion of hospitalised patients worsen, sometimes due to reversible causes. Failure to identify and act on indicators of worsening acute illness in hospital wards is a problem that has been known for more than 10 years. "Track and Trigger" scoring systems are used in practice to check "standard" vital signs. These are pulse rate, respiratory rate, blood pressure, oxygen level and temperature. These are taken at timed intervals based on a protocol which is selected based on the clinical condition of the patient. Intermittent application of vital sign monitoring devices can be time-consuming. As a result the correct frequency of observations is often missed. Continuous vital sign monitoring within the ward environment is not currently workable, but it's believed to increase the timely detection of patient deterioration. Wearable ambulatory monitoring systems (AMS) may provide an alternative continuous monitoring system which may improve the early detection of irregular physical and biological parameters. AMS would allow patients to be more mobile and have less discomfort. The aim of this study is to test whether the devices will be able to give correct readings and be suitable for clinical use. This is to ensure that AMS kits give accurate and reliable readings. To achieve this these kits need to be rigorously tested on 30 healthy volunteers.

### Who can participate?

Men and women aged 18 or over and in generally good health

### What does the study involve?

Participants will be attached to a standard hospital monitor and the portable monitors being tested. A small tube will be inserted into their radial artery (called an arterial line). This will allow the study doctor to take blood samples during the study. Participants will be asked to follow a series of movements designed to mimic those commonly made by patients in hospital, such as drinking, standing and reading. They will then be asked to wear a tight-fitting mask attached to a machine. This will gradually lower the amount of oxygen in their blood. Throughout the study, blood samples will be taken from the arterial line to measure blood oxygen levels. At the end of the study the mask will be removed, oxygen levels returned to normal and the arterial line will be removed.

What are the possible benefits and risks of participating?

The risks involved in participation in this study are few. The procedures to be carried out in this study are generally well tolerated. The member of the research team carrying out these procedures will have done them a great number of times before and be technically skilled so as to minimise discomfort. Although rare, there is always a risk of minimal complications during arterial line placement and decreased oxygen exposure, for example bruising and fainting. Other rare complications of the arterial line can include temporary vascular occlusion, thrombosis, ischemia, hematoma formation, and local and catheter-related infection, sepsis and nerve damage. If symptoms become unpleasant, the testing will be stopped. These side effects should rapidly reverse following breathing normal room air.

Where is the study run from?

John Radcliffe Hospital (UK)

When is the study starting and how long is it expected to run for?

May 2018 to March 2022

Who is funding the study?

NIHR Oxford Biomedical Research Centre (UK)

Who is the main contact?

Dr Sarah Vollam

Sarah.vollam@ndcn.ox.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Dr Sarah Vollam

### ORCID ID

<https://orcid.org/0000-0003-2835-6271>

### Contact details

Nuffield Department of Clinical Neurosciences, University of Oxford

Kadoorie Centre

Level 3

John Radcliffe Hospital

Oxford

United Kingdom

OX3 9DU

+44 (0)1865231440

Sarah.vollam@ndcn.ox.ac.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

251711

## Study information

### Scientific Title

Virtual HDU: hypoxia study. Accuracy and validity testing of ambulatory monitoring system

### Acronym

vHDU-Hypoxia

### Study objectives

The primary objective of the study is to determine the specificity and sensitivity of commercially available ambulatory vital-sign monitoring equipment for detection of hypoxia. This phase of the study will test the ambulatory monitoring equipment on healthy volunteers.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 15/03/2019, East of Scotland Research Ethics Service REC 2 (Tayside Medical Science Centre, Residency Block Level 3, George Pirie Way, Ninewells Hospital and Medical School, Dundee DD1 9SY, Tel: +44 (0)1382 383878; Email: eosres.tayside@nhs.net), ref: 19/ES/0008

### Study design

Observational cross-sectional cohort study

### Primary study design

Observational

### Study type(s)

Diagnostic

### Health condition(s) or problem(s) studied

Vital sign monitoring

### Interventions

Participants will visit the designated research facility for the study visit. On arrival, participants will be assessed for their suitability for the study. An arterial line will be inserted into their radial artery. They will be connected to a standard hospital monitor and the ambulatory monitors being tested. Throughout the study, data from all monitors will be recorded. In the movement phase, participants will follow a series of protocolised movements designed to replicate usual patient movements. Arterial blood samples will be taken at the end of each movement. During the hypoxia phase, participants will lie on a bed with a tight face mask delivering reduced levels of inhaled oxygen. Their blood oxygen levels will be monitored and arterial blood gases taken at intervals as their oxygen saturations decrease. Throughout the procedures, an anaesthetist will be present and their vital signs closely monitored for safety purposes. After the hypoxia phase,

their blood oxygen levels will be normalised and the arterial line removed. They will remain with the study team until deemed to have recovered sufficiently to leave the research facility.

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Not provided at time of registration

**Primary outcome(s)**

Specificity and sensitivity of currently available ambulatory vital-sign monitors will be assessed by comparing continuous oxygen saturation, pulse rate and breathing rate data from each ambulatory monitor with arterial blood oxygen saturation measured through blood gas analysis, respiratory rate derived from capnography and pulse rate derived from 'usual care' hospital grade pulse oximetry monitoring. Arterial oxygen saturation will be measured at incremental drops in SpO<sub>2</sub>, up to 80%. Respiratory rate and pulse rate will be measured continuously throughout testing.

**Key secondary outcome(s)**

The effects of movement on data acquisition by currently available ambulatory vital-sign monitors will be assessed by comparing continuous oxygen saturation, pulse rate and breathing rate data from each ambulatory monitor with arterial blood oxygen saturation measured through blood gas analysis, respiratory rate derived from capnography and pulse rate derived from 'usual care' hospital grade pulse oximetry monitoring. Arterial oxygen saturation will be measured after each movement is completed. Respiratory rate and pulse rate will be measured continuously throughout testing.

**Completion date**

01/03/2022

**Eligibility****Key inclusion criteria**

1. Willing and able to give informed consent for participation in the study
2. Men and women aged 18 or over and in generally good health

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

29

**Key exclusion criteria**

1. Allergies to adhesive dressings (such as bio-occlusive dressings or micropore) or local anesthetic (e.g. Lidocaine)
2. Intra-cardiac device (e.g. Permanent pacemaker) or previous wrist arterial line
3. Epilepsy
4. Angina, congenital heart disease or history of severe cardiopulmonary disease
5. History of anaemia (reported in the pre-screening telephone call) or Hb below 100 g/l on first test
6. Resting hypoxaemia (SpO2 <94%) or significant cardiopulmonary disease rendering exposure to alveolar hypoxia unsafe, as determined by the research physician
7. Pregnancy or breastfeeding
8. Clotting disorders and use of antiplatelet or anticoagulant medication (such as Aspirin)
9. Claustrophobia precluding spell in the hypoxic exposure

**Date of first enrolment**

18/06/2019

**Date of final enrolment**

01/09/2019

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**John Radcliffe Hospital**

Critical Care Research Group

Kadoorie Centre

Headley Way

Oxford

United Kingdom

OX3 9DU

**Sponsor information****Organisation**

University of Oxford

ROR

<https://ror.org/052gg0110>

## Funder(s)

**Funder type**

Government

**Funder Name**

NIHR Oxford Biomedical Research Centre

## Results and Publications

### Individual participant data (IPD) sharing plan

De-identified data will be held with the University of Oxford electronic archive for 5 years after the end of the study. Datasets will be large and focused on validation of monitor outputs. However, de-identified datasets may be made available to researchers on written request to the PI (Dr Peter Watkinson: [peter.watkinson@ndcn.ox.ac.uk](mailto:peter.watkinson@ndcn.ox.ac.uk)).

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	15/09/2021	21/09/2021	Yes	No
<a href="#">Results article</a>		15/02/2022	16/02/2022	Yes	No
<a href="#">Protocol article</a>		12/01/2020	19/07/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes